Hypoplastic Left Heart Syndrome (HLHS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033 thelansis.com

Hypoplastic Left Heart Syndrome (HLHS) is a multifaceted cardiac malformation, likely originating from numerous developmental errors during the initial stages of cardiogenesis. If not treated, it is invariably fatal. HLHS is characterized by an array of chest radiographic findings, including an enlarged cardiac silhouette (with a notably prominent right atrium), pulmonary venous hypertension, an atrial septal defect, and valvular stenosis or atresia. In patients with HLHS, pulmonary venous blood enters the left atrium, but the atretic or stenotic mitral valve prevents the atrial systole from pushing blood into the hypoplastic left ventricle. HLHS predominantly affects males and is known to have a genetic predisposition in certain families. However, the complete genetic etiology remains elusive—approximately 12% of infants with HLHS present with associated extracardiac anomalies. Genetic disorders linked with HLHS include Turner syndrome, Holt-Oram syndrome, Smith-Lemli-Opitz syndrome, Noonan syndrome, and trisomies 13, 18, and 21. The left atrial blood is diverted across interatrial communication, ranging from a highly restrictive foramen ovale to a wide, nonrestrictive atrial septal defect. The most common scenario involves a restrictive foramen ovale that limits left-to-right shunting. This limited flow, combined with reduced flow through the mitral valve, results in pulmonary venous outflow obstruction, leading to the typical presentation of a neonate with severe congestive heart failure. The standard treatment involves open-heart surgery to redirect the oxygen-rich (“red”) and oxygen-poor (“blue”) blood. The “Staged Reconstruction,” a series of three reconstructive operations — the Norwood, Glenn, and Fontan procedures — is employed to repair HLHS.
• HLHS has a reported prevalence of 0.2 per 1,000 live births and is twice as common in boys as in girls. If left untreated, HLHS is invariably lethal, accounting for 25% of early cardiac deaths in neonates.

Thelansis’s “Hypoplastic Left Heart Syndrome (HLHS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033″ covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hypoplastic Left Heart Syndrome (HLHS) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Hypoplastic Left Heart Syndrome (HLHS) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Hypoplastic Left Heart Syndrome (HLHS) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Hypoplastic Left Heart Syndrome (HLHS) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Tags: Hypoplastic Left Heart Syndrome (HLHS), Hypoplastic Left Heart Syndrome (HLHS) market outlook, Hypoplastic Left Heart Syndrome (HLHS) competitive landscape, Hypoplastic Left Heart Syndrome (HLHS) market forecast, Thelansis, Primary market research, KOL insights, Competitive Intelligence (CI)